Home Compounds Growth Hormone Axis HGH 191AA
Growth Hormone Axis Research High Evidence

HGH 191AA

Recombinant human growth hormone (somatropin). Most studied peptide hormone with decades of clinical trial data across multiple indications.

somatropinhghgrowth hormoneigf-1body compositionaging
Half-life
2–4 hours SQ
SKUs
4
Evidence
High Evidence

HGH-191aa refers to recombinant human growth hormone — a synthetic version of the naturally occurring 191 amino acid growth hormone protein. It is identical in structure to pituitary-derived human growth hormone. It is FDA-approved for specific medical conditions and is one of the most well-studied protein hormones in clinical medicine, though its off-label use for performance and anti-aging purposes lacks strong evidence.

Growth Hormone Deficiency
Recombinant HGH is FDA-approved for growth hormone deficiency in children and adults. Large controlled trials demonstrate that it restores normal growth in GH-deficient children and improves body composition, bone density, and quality of life in GH-deficient adults.
Body Composition Research
In GH-deficient adults, HGH treatment produces significant increases in lean mass and reductions in fat mass. In adults without GH deficiency, the effects are smaller and the benefit-to-risk profile is less favorable. Research in normal older adults shows modest body composition changes but increased side effects.
Aging and Longevity Research
GH levels naturally decline with age. Research has examined whether HGH supplementation in older adults can reverse aspects of age-related physical decline. The NEJM Rudman study (1990) created popular interest, but subsequent research has not shown the hoped-for longevity or health benefits in people without GH deficiency.
Pediatric Applications
Beyond GH deficiency, HGH is approved for several specific pediatric conditions including Turner syndrome, Prader-Willi syndrome, and children born small for gestational age. These approvals are based on controlled trial evidence.
  • Highly effective for FDA-approved indications — GH deficiency in children and adults.
  • Significant body composition improvements in truly GH-deficient patients.
  • Modest and variable effects in people without GH deficiency, with increased side effect rates.
  • Anti-aging effects in healthy older adults are not well-established despite popular belief.
  • Long-term safety concerns include potential effects on cancer risk and metabolic parameters.

The research strongly supports HGH use in GH deficiency but does not strongly support it as an anti-aging or performance compound in people with normal GH levels. Side effects — including fluid retention, joint pain, carpal tunnel syndrome, glucose intolerance, and potential cancer risk — are meaningful, particularly at higher doses used outside of medical supervision. It is a prescription-only medication.

Your pituitary gland produces growth hormone in pulses, primarily during sleep and exercise. GH drives growth in children and continues to regulate body composition, bone density, and metabolism throughout life. It works by stimulating the liver and other tissues to produce IGF-1, which then acts on muscle, fat, and bone cells directly. As you age, GH production gradually declines. Recombinant HGH is a laboratory-produced version identical to what your pituitary makes. Injecting it directly replaces the signal, driving IGF-1 production and the downstream metabolic effects. In GH-deficient people, this restores a missing signal. In people who already produce normal GH, adding more does not necessarily produce proportional benefits and increases the risk of side effects.

FDA-approved with a well-established safety profile for approved medical uses. Side effects at therapeutic doses include fluid retention, joint and muscle pain, and potential worsening of insulin resistance. Long-term use at higher doses is associated with acromegaly-like effects, increased cardiovascular risk, and concerns about cancer promotion given IGF-1's role in cell growth signaling. Requires prescription and medical supervision.

High Evidence

This compound has been studied in multiple large randomized controlled trials with human subjects. The evidence base is strong and consistent across independent research groups.

Published Research Ranges
0.01–0.04mg/kg/day studied; varies significantly by indication in trials
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

Recombinant Human Growth Hormone in Growth Hormone Deficiency: A Meta-Analysis
Journal of Clinical Endocrinology & Metabolism • 2009  • DOI: 10.1210/jc.2009-0185
View Source
Growth Hormone and Body Composition in Adults: The ACROSTUDY
European Journal of Endocrinology • 2012  • DOI: 10.1530/EJE-12-0244
View Source
Growth Hormone Replacement in Adults: Clinical Benefits and Safety
New England Journal of Medicine • 1989  • DOI: 10.1056/NEJM198907273210401
View Source
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
 • 2022  • DOI: 10.1210/clinem/dgac220
View Source
Growth hormone plus childhood low-dose estrogen in Turner's syndrome
 • 2011  • DOI: 10.1056/nejmoa1005669
View Source
Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years
 • 2008  • DOI: 10.1210/jc.2007-1559
View Source
Long-term persistance of the pathophysiologic response to severe burn injury
 • 2011  • DOI: 10.1371/journal.pone.0021245
View Source
Human growth hormone prevents the protein catabolic side effects of prednisone in humans
 • 1990  • DOI: 10.1172/jci114694
View Source
The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
 • 2020  • DOI: 10.1002/cpt.1836
View Source
A Systematic Review of Insulin Adherence Measures in Patients with Diabetes
 • 2016  • DOI: 10.18553/jmcp.2016.22.11.1224
View Source
Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: 
a systematic review
 • 2015  • DOI: 10.11613/bm.2015.018
View Source
PEGylated therapeutics in the clinic
 • 2024  • DOI: 10.1002/btm2.10600
View Source
The molecular mechanisms of cardiac development and related diseases
 • 2024  • DOI: 10.1038/s41392-024-02069-8
View Source
Genetics of Obesity in Humans: A Clinical Review
 • 2022  • DOI: 10.3390/ijms231911005
View Source
The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules
 • 2022  • DOI: 10.3390/molecules27031075
View Source
Peptide-Drug Conjugates: A New Hope for Cancer Management
 • 2022  • DOI: 10.3390/molecules27217232
View Source
Molecular Probes, Chemosensors, and Nanosensors for Optical Detection of Biorelevant Molecules and Ions in Aqueous Media and Biofluids
 • 2022  • DOI: 10.1021/acs.chemrev.1c00746
View Source
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach
 • 2021  • DOI: 10.1016/j.jaip.2020.12.047
View Source
T cell regeneration after immunological injury
 • 2021  • DOI: 10.1038/s41577-020-00457-z
View Source
Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine
 • 2021  • DOI: 10.1016/j.xcrm.2021.100346
View Source
Oral delivery of proteins and peptides: Challenges, status quo and future perspectives
 • 2021  • DOI: 10.1016/j.apsb.2021.04.001
View Source
A Review of the Microbial Production of Bioactive Natural Products and Biologics
 • 2019  • DOI: 10.3389/fmicb.2019.01404
View Source
Evolution of the EU Biosimilar Framework: Past and Future
 • 2019  • DOI: 10.1007/s40259-019-00377-y
View Source
Butterfly Pea (Clitoria ternatea), a Cyclotide-Bearing Plant With Applications in Agriculture and Medicine
 • 2019  • DOI: 10.3389/fpls.2019.00645
View Source
Advances in Biomaterials for Drug Delivery
 • 2018  • DOI: 10.1002/adma.201705328
View Source
A guide to maximizing the therapeutic potential of protein-polymer conjugates by rational design
 • 2018  • DOI: 10.1039/c8cs00606g
View Source
Heat: A Highly Efficient Skin Enhancer for Transdermal Drug Delivery
 • 2018  • DOI: 10.3389/fbioe.2018.00015
View Source
Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics
 • 2018  • DOI: 10.1007/s40005-017-0370-4
View Source
Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community
 • 2017  • DOI: 10.1007/s40259-017-0218-5
View Source
Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
 • 2016  • DOI: 10.3109/07388551.2015.1084266
View Source
Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial
 • 2021  • DOI: 10.1210/clinem/dgab529
View Source
Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
 • 2020  • DOI: 10.1210/clinem/dgaa049
View Source
Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone
 • 2020  • DOI: 10.1111/cen.14273
View Source
Effect of low-normal and high-normal IGF-1 levels on memory and wellbeing during growth hormone replacement therapy: a randomized clinical trial in adult growth hormone deficiency
 • 2018  • DOI: 10.1186/s12955-018-0963-2
View Source
Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency
 • 2016  • DOI: 10.1210/jc.2015-1991
View Source
Citrulline stimulates muscle protein synthesis in the post-absorptive state in healthy people fed a low-protein diet - A pilot study
 • 2015  • DOI: 10.1016/j.clnu.2014.04.019
View Source
Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study
 • 2014  • DOI: 10.1016/j.nmd.2013.10.011
View Source
Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial
 • 2012  • DOI: 10.1530/eje-11-1068
View Source
Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement
 • 2005  • DOI: 10.1016/j.psyneuen.2004.05.004
View Source
Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study
 • 1996  • DOI: 10.1172/jci119095
View Source
Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
 • 2022  • DOI: 10.1159/000524003
View Source
Final adult height in children with congenital adrenal hyperplasia treated with growth hormone
 • 2011  • DOI: 10.1210/jc.2010-2699
View Source
The influence of growth hormone on pediatric body composition: A systematic review
 • 2023  • DOI: 10.3389/fendo.2023.1093691
View Source
The potential effects of anabolic-androgenic steroids and growth hormone as commonly used sport supplements on the kidney: a systematic review
 • 2019  • DOI: 10.1186/s12882-019-1384-0
View Source
Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies
 • 2015  • DOI: 10.1007/s11357-014-9742-0
View Source
Recombinant growth hormone therapy for cystic fibrosis in children and young adults
 • 2013  • DOI: 10.1002/14651858.cd008901.pub2
View Source
An evidence-based review of aging of the body systems following spinal cord injury
 • 2011  • DOI: 10.1038/sc.2010.178
View Source
Impaired quality of life in hypopituitary adults with growth hormone deficiency : can somatropin replacement therapy help?
 • 2006  • DOI: 10.2165/00024677-200605040-00005
View Source
Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023
 • 2024  • DOI: 10.3390/biomedicines12091992
View Source
Anabolic Resistance in the Pathogenesis of Sarcopenia in the Elderly: Role of Nutrition and Exercise in Young and Old People
 • 2023  • DOI: 10.3390/nu15184073
View Source
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
 • 2022  • DOI: 10.1007/s00210-022-02250-2
View Source
Human Growth and Growth Hormone: From Antiquity to the Recominant Age to the Future
 • 2021  • DOI: 10.3389/fendo.2021.709936
View Source
Placental Endocrine Activity: Adaptation and Disruption of Maternal Glucose Metabolism in Pregnancy and the Influence of Fetal Sex
 • 2021  • DOI: 10.3390/ijms222312722
View Source
Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs
 • 2021  • DOI: 10.3389/fendo.2021.637209
View Source
Insulin-Like Growth Factor-1: A Promising Therapeutic Target for Peripheral Nerve Injury
 • 2021  • DOI: 10.3389/fbioe.2021.695850
View Source
Heightened susceptibility: A review of how pregnancy and chemical exposures influence maternal health
 • 2020  • DOI: 10.1016/j.reprotox.2019.04.004
View Source
Biological basis of bone strength: anatomy, physiology and measurement
 • 2020
View Source
Cardiac Cachexia: A Well-Known but Challenging Complication of Heart Failure
 • 2020  • DOI: 10.2147/cia.s273967
View Source
Paracrine signaling in islet function and survival
 • 2020  • DOI: 10.1007/s00109-020-01887-x
View Source
The evolving therapeutic landscape of genetic skeletal disorders
 • 2019  • DOI: 10.1186/s13023-019-1222-2
View Source

60 sources · Platform research library · Not generated by AI

H10H15H24H36

Want More Detailed Research?

Ask the AI anything about HGH 191AA - mechanisms, trial summaries, pharmacokinetics, and comparisons.

Ask AI About HGH 191AA
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.